Compare AstraZeneca plc (AZN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Revvity Inc — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: AstraZeneca plc is far larger — about 19.2× Revvity Inc's market cap, and AstraZeneca plc pays the higher dividend (2.01%). Which is the better fit depends on your goals.
| AZN | RVTY | |
|---|---|---|
Market Cap | $248.14B | $12.91B |
Sector | Health | Technology |
52-Week High | $209.48 | $117.75 |
52-Week Low | $147.06 | $82.26 |
Enterprise Value | $275.41B | $15.23B |
Dividend Yield | 2.01% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
